Heartflow (NASDAQ:HTFL) Insider Sells $261,266.46 in Stock

Heartflow, Inc. (NASDAQ:HTFL) insider Campbell Rogers sold 9,219 shares of Heartflow stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $28.34, for a total transaction of $261,266.46. Following the sale, the insider owned 78,731 shares of the company’s stock, valued at approximately $2,231,236.54. This represents a 10.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Campbell Rogers also recently made the following trade(s):

• On Wednesday, April 1st, Campbell Rogers sold 64,533 shares of Heartflow stock. The shares were sold at an average price of $24.64, for a total transaction of $1,590,093.12.
• On Thursday, March 19th, Campbell Rogers sold 64,533 shares of Heartflow stock. The shares were sold at an average price of $25.69, for a total transaction of $1,657,852.77.

Heartflow Stock Up 2.9%

Shares of HTFL traded up $0.78 during trading on Wednesday, reaching $27.38. 1,091,812 shares of the company traded hands, compared to its average volume of 1,397,840. Heartflow, Inc. has a twelve month low of $20.13 and a twelve month high of $41.22. The stock has a market cap of $2.36 billion and a PE ratio of -8.80. The stock has a 50-day simple moving average of $27.37 and a 200-day simple moving average of $28.63.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.08. The company had revenue of $52.59 million for the quarter. The firm’s revenue was up 41.3% compared to the same quarter last year. On average, equities research analysts predict that Heartflow, Inc. will post -0.78 EPS for the current year.

Institutional Investors Weigh In On Heartflow

Large investors have recently bought and sold shares of the stock. Emerald Mutual Fund Advisers Trust purchased a new position in Heartflow in the third quarter worth approximately $4,418,000. TrueMark Investments LLC purchased a new position in Heartflow in the third quarter worth approximately $918,000. Baillie Gifford & Co. purchased a new position in Heartflow in the third quarter worth approximately $101,182,000. Y Intercept Hong Kong Ltd purchased a new position in Heartflow in the third quarter worth approximately $234,000. Finally, New York State Common Retirement Fund purchased a new position in Heartflow in the third quarter worth approximately $4,015,000.

Analyst Ratings Changes

Several research analysts have recently commented on HTFL shares. Canaccord Genuity Group lowered their price objective on shares of Heartflow from $43.00 to $37.00 and set a “buy” rating for the company in a research note on Friday, May 15th. William Blair started coverage on shares of Heartflow in a research note on Monday, May 4th. They issued an “outperform” rating for the company. Wells Fargo & Company raised their price objective on shares of Heartflow from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Finally, JPMorgan Chase & Co. lowered their price objective on shares of Heartflow from $40.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday, March 19th. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $37.00.

About Heartflow

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.